DEEP DIVE
COMPANION TO ISSUE #37 · 18 NOVEMBER 2026
Up Is Not the Same as Better
Why doubling your blood NAD+ hasn’t made healthy people measurably younger, whether NAD+ even falls with age, where boosting has helped, and the safety question nobody has answered.
For a decade the NAD+ pitch has rested on three sentences. NAD+ falls as you age. The fall helps drive ageing. Top it up and you push back.
Issue 37 graded the third sentence: in healthy people, blood NAD+ doubled and little else followed; in people with a specific medical problem, a few trials did better. This piece looks at the first two sentences, because they bear on that split. I expected to find a clean human decline that supplements were failing to fix. That’s not what the data showed.
Which row is yours
Most readers fit more than one row. The table sets out evidence, not advice; the issue’s Biohacking Corner covers what to do.
Are 35–60 and healthy
What trials show: Boosters reliably raise blood NAD+. No trial shows a health benefit.
What they do not show: That boosters slow ageing.
Train three or more times a week
What trials show: In one snapshot study, trained older adults had muscle NAD+ close to young adults.
What they do not show: That training raises NAD+, or that you need a top-up.
Have had two or more non-melanoma skin cancers in five years
What trials show: Nicotinamide 500 mg twice daily cut new ones 23% during a year of treatment.
What they do not show: Any benefit after stopping, or in people without past skin cancers.
Are over 60 and losing strength
What trials show: 10 NMN and NR trials found no effect on muscle or strength.
What they do not show: Any muscle benefit from either.
Have leg artery disease
What trials show: One 90-person NR trial improved a six-minute walk.
What they do not show: A confirmed benefit. It needs repeating.
Have Parkinson’s
What trials show: A 410-person, year-long NR trial found no benefit.
What they do not show: That NR slows the disease.
Where a row shows a benefit, it’s in people with a specific medical problem. Whether that’s because they were short of NAD+ is still an open question.
What “declines with age” actually measured
The decline is clearest in animals. In humans, a 2020 review by Joseph Baur’s group at the University of Pennsylvania found reported falls of roughly 10–25% in brain scans and about 14% in spinal fluid, with one unreviewed brain study finding no consistent difference at all.
Then 2026 brought two careful looks at blood, where most supplement trials measure. In May, an Amsterdam team led by Riekelt Houtkooper and Georges Janssens reported 303 people across seven groups, from under-30s to frail over-60s and elite athletes. Blood NAD+ didn’t differ with age, and didn’t shift when frail older adults exercised or ate more protein. Their test did pick up the rise from NR, so it wasn’t blind. The authors declared no competing interests.
In November, a Vilnius University team led by Dalius Ratautas reported 1,068 Lithuanian adults tested with a finger-prick method the team developed. Among 707 healthy people taking no NAD+ supplements, levels didn’t fall with age: flat in men, slightly rising in women. Lower NAD+ tracked heart disease and high blood pressure, which grow commoner with age, so earlier studies may have mistaken a disease effect for an ageing one. It’s observational, the sick group was on medication, and the work was run with two Lithuanian companies, SensoLife and LifeLab1.
McReynolds et al. Exp Gerontol (2020) · Trętowicz et al. Nat Metab (2026) · The Scientist on Trętowicz et al. (2026) · Vilnius University (Ratautas group). Nat Metab (2026) · Vilnius University release (2026)
Muscle may be different. In 2022 the same Amsterdam group found NAD+ lower in older muscle overall. But trained older adults had levels close to the young, the physically impaired had the lowest of all, and NAD+ tracked daily steps. That’s a snapshot, not a trial. Separately, five small studies found exercise raised NAMPT, an enzyme that recycles NAD+ in muscle, by about 1.5-fold; that’s an enzyme, not NAD+ itself.
In healthy people, blood NAD+ doesn’t behave like a clock. Whether low muscle NAD+ reflects inactivity, disease or age is still open.
Where boosting has helped, and why is still open
If low NAD+ mostly signals trouble, boosters might work best where there is trouble. That’s a hypothesis. The evidence for it is suggestive, not settled.
A measured deficiency. In 2020, a University of Helsinki team found low NAD+ in the blood and muscle of patients with adult-onset mitochondrial myopathy, a rare inherited muscle disease. Niacin, plain B3 built up to 750–1,000 mg a day, raised their muscle NAD+ 1.3-fold at four months and 2.3-fold at ten. Healthy controls on the same regimen showed no rise in muscle NAD+. Strength improved in both groups, though, so not all of the gain can be credited to fixing a deficit. It was small and open, without placebo, and niacin nudged up fasting glucose.
Tissue under strain. The positive trials in Issue 37 share a feature: sun-damaged skin in people who’d had repeated cancers, leg muscles starved of blood in arterial disease, muscle that had stopped responding well to insulin in prediabetes. None of them measured NAD+ before treatment, so none shows a deficit was the reason it worked.
Pirinen et al. Cell Metab (2020) · Chen et al. (ONTRAC). N Engl J Med (2015) · McDermott et al. Nat Commun (2024) · Yoshino et al. Science (2021)
Is a deficit what makes a booster useful? No trial has tested that directly. It’s the question the next trials should be built around.
The number in the blood
In the 2026 Nestlé head-to-head, NR and NMN each roughly doubled blood NAD+ within two weeks. Lab work in the same paper, and a 2025 mouse study, suggest gut bacteria turn much of both into nicotinic acid, an older form of B3, along the way.
Some of it reaches tissue. In a 2019 Birmingham trial, NR raised NAD+-related metabolites in older men’s muscle without changing mitochondrial function. In the 2022 NADPARK pilot, brain NAD+ rose in most patients; the full trial still failed. The Amsterdam team’s verdict on blood NAD+ is that it shows whether a supplement is being absorbed, not what’s happening in tissue. Delivery doesn’t look like the bottleneck.
Christen et al. Nat Metab (2026) · Yaku et al. Sci Adv (2025) · Elhassan et al. Cell Rep (2019) · Brakedal et al. Cell Metab (2022) · NOPARK trial. JAMA (2026)
Two other reasons healthy trials come back null
Wrong compartment. NAD+ sits in separate pools inside cells, and the Baur review flags poor subcellular resolution in most studies. The pool inside mitochondria may be the one that matters, and no blood test sees it.
Cause or consequence. Lower NAD+ in old, inactive muscle may follow declining function rather than drive it. If so, raising it with a pill would be like repainting a fuel gauge.
Neither is proven, but alongside “nothing to fix” they fit the pattern better than “the dose was too low”.
The open safety question
Extra B3, whatever form it arrives in, has to leave eventually. Its terminal breakdown products include two molecules called 2PY and 4PY.
In 2024, a Cleveland Clinic team led by Stanley Hazen reported in Nature Medicine that higher blood 4PY was linked to heart attack, stroke and death over three years in two cohorts of cardiac patients: 2,331 in the US (hazard ratio 1.89) and 832 in Europe (1.99). A gene variant that raises 4PY was tied to a marker of blood-vessel inflammation, and in mice, 4PY at normal physiological levels made vessel walls stickier for white cells.
That is association in people who were already ill, plus a mouse mechanism. Those hazard ratios describe cardiac patients’ own 4PY levels; they don’t estimate the risk of taking any particular B3 supplement, including the nicotinamide that worked for skin cancer. Some booster trials have measured 2PY and 4PY, including the 2021 NMN study in prediabetic women, but none has followed people long enough to ask whether it matters for the heart. It’s an open question, not a warning, and the reason B3 at supplement doses is worth taking only with a clear purpose. I’d like 4PY reported, and followed up, in every long-term booster trial.
What would change the grades
Four results would move this. First, a booster trial in people shown to be low, such as frail older adults with muscle NAD+ measured first and strength as the outcome. Second, a larger leg-artery trial: if 17.6 m holds in a few hundred patients, that C becomes a B. Third, the glaucoma trials. In a Columbia phase 2 trial, 42 patients were randomised and 32 completed; those on nicotinamide combined with pyruvate had more improving visual-field test points than placebo after about two months. A 12-week Korean crossover in 2026 found no visual-field difference, and larger trials now running, including the UK’s phase 3 NAMinG, should settle it. Fourth, 4PY tracked in long-term booster trials, so the safety question gets an answer either way.
McDermott et al. Nat Commun (2024) · De Moraes et al. JAMA Ophthalmol (2022) · Ha et al. Br J Ophthalmol (2026) · NAMinG phase 3 trial registration (ISRCTN16435278)
What this means for you
The plan lives in this week’s issue. This piece asks whether there’s a gap for a capsule to fill.
For healthy readers, the 2026 blood studies make the usual pitch harder to sustain: the decline the boosters promise to reverse doesn’t show up in their blood. For readers in the skin-cancer row, there’s a tested option for a specific risk, to discuss with a dermatologist. That’s arguably the most useful thing NAD+ research has produced so far, and it came from a vitamin, not a patent.
This is the Issue 37 Deep Dive. Longevity Latest grades interventions like this every Wednesday: what works, what’s premature, and what’s just marketing. Next week’s issue: rapamycin, back from Issue 03 with new human trial data.
Already a reader? Reply and tell me which rows you’re in.
Sources and further reading
Evidence reviewed through 17 November 2026. The Vilnius study used dried blood spots; the companies’ roles are as described by the research team. One Trętowicz et al. cohort was funded by Nestlé Health Science. Janssens et al. was cross-sectional. Pirinen et al. was open-label with matched healthy controls; whole-blood NAD+ rose in both groups, muscle NAD+ only in patients. The gut-conversion finding in Christen et al. comes from lab work; nicotinic acid was not detected in participants’ blood. Elhassan et al. was a 12-person crossover. In Ferrell et al., hazard ratios are adjusted three-year risks for major adverse cardiac events (95% CI 1.26–2.84 US, 1.26–3.14 Europe) in stable cardiac patients, not supplement users. The Korean glaucoma crossover is Ha et al., Br J Ophthalmol (2026). Educational content only; speak to your doctor before taking any form of B3 at supplement doses if you have liver disease, cancer, Parkinson’s or a transplant, or are pregnant or breastfeeding.